Derived from human biology, engineered for human health. Infinimmune systematically surfaces and engineers the rare antibodies evolution has already proven in people and advances them into the clinic.
Infinimmune closes a $75 million Series A co-led by Regeneron Ventures and Playground Global. RA Capital Management, Forge Life Science Partners, and Goldcrest Capital also participate in the financing, which will advance the company’s IFX-101 and IFX-201 programs toward phase 1.
Merck signs a multi-target research and development collaboration with antibody discovery startup Infinimmune, worth up to $838 million. The companies will discover immune cell-directed antibodies against multiple targets.
KBI Biopharma collaborates with Infinimmune to support manufacturing of Infinimmune’s lead human monoclonal antibody, IFX-101. KBI will provide process development and manufacturing services for the antibody.
Infinimmune launches GLIMPSE-1, a protein language model for antibody engineering and optimization. The model is trained solely on paired human antibody sequences, using human-sourced data as the basis for its work on designing and refining antibodies.
